UPR vs. UDG, MDC, BTG, ABC, HCM, INDV, GNS, CLIN, EMIS, and ONT
Should you be buying Uniphar stock or one of its competitors? The main competitors of Uniphar include UDG Healthcare (UDG), Mediclinic International (MDC), BTG (BTG), Abcam (ABC), HUTCHMED (HCM), Indivior (INDV), Genus (GNS), Clinigen Group (CLIN), EMIS Group (EMIS), and Oxford Nanopore Technologies (ONT). These companies are all part of the "medical" sector.
Uniphar vs. Its Competitors
Uniphar (LON:UPR) and UDG Healthcare (LON:UDG) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking.
Uniphar pays an annual dividend of GBX 2 per share and has a dividend yield of 0.6%. UDG Healthcare pays an annual dividend of GBX 0.17 per share. Uniphar pays out 13.9% of its earnings in the form of a dividend. UDG Healthcare pays out 0.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Uniphar has a net margin of 1.68% compared to UDG Healthcare's net margin of 0.00%. Uniphar's return on equity of 13.18% beat UDG Healthcare's return on equity.
In the previous week, Uniphar had 1 more articles in the media than UDG Healthcare. MarketBeat recorded 1 mentions for Uniphar and 0 mentions for UDG Healthcare. Uniphar's average media sentiment score of 0.00 equaled UDG Healthcare'saverage media sentiment score.
Uniphar has higher revenue and earnings than UDG Healthcare. UDG Healthcare is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.
UDG Healthcare received 510 more outperform votes than Uniphar when rated by MarketBeat users. However, 100.00% of users gave Uniphar an outperform vote while only 74.68% of users gave UDG Healthcare an outperform vote.
45.3% of Uniphar shares are held by institutional investors. 10.1% of Uniphar shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Uniphar presently has a consensus price target of GBX 310, indicating a potential downside of 5.04%. Given UDG Healthcare's higher possible upside, analysts clearly believe UDG Healthcare is more favorable than Uniphar.
Summary
Uniphar beats UDG Healthcare on 11 of the 16 factors compared between the two stocks.
Get Uniphar News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding UPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:UPR) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy UPR Stock Free UPR Stock Alerts